Bausch + Lomb Corporation (BLCO)
- Previous Close
13.72 - Open
11.70 - Bid --
- Ask 14.27 x 1200
- Day's Range
10.45 - 12.00 - 52 Week Range
10.45 - 21.69 - Volume
4,131,554 - Avg. Volume
800,259 - Market Cap (intraday)
4.084B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.90 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.31
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
www.bausch.com13,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: BLCO
View More
Performance Overview: BLCO
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLCO
View MoreValuation Measures
Market Cap
3.90B
Enterprise Value
8.37B
Trailing P/E
--
Forward P/E
12.80
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.85
Price/Book (mrq)
0.63
Enterprise Value/Revenue
1.75
Enterprise Value/EBITDA
13.93
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.62%
Return on Assets (ttm)
0.96%
Return on Equity (ttm)
-4.53%
Revenue (ttm)
4.79B
Net Income Avi to Common (ttm)
-317M
Diluted EPS (ttm)
-0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
305M
Total Debt/Equity (mrq)
75.43%
Levered Free Cash Flow (ttm)
188.38M
Research Analysis: BLCO
View MoreResearch Reports: BLCO
View MoreBausch & Lomb Earnings: Amid Tariff and Recall Concerns, Shares Sink on Shaky Start to 2025
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice TargetTariffs Raise Near-Term Uncertainty for Vision Care Firms, Especially for Struggling Ones
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice TargetTariffs Raise Near-Term Uncertainty for Vision Care Firms, Especially for Struggling Ones
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice TargetTariffs Raise Near-Term Uncertainty for Vision Care Firms, Especially for Struggling Ones
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice Target